CHICAGO / BERLIN:The handful of drugmakers dominating the global coronavirus vaccine race are pushing the boundaries of vaccine technology. The next crop under development feature more conventional, proven designs.
The world will need several different vaccines to fight the COVID-19 pandemic, given the sheer size of global need, variations in effects on different populations, and possible limits of effectiveness in the first crop.
Many leading candidates now in final-stage testing are based on new, largely unproven technology platforms designed to produce vaccines at speed.
They include messenger RNA (mRNA) technology used by Moderna Inc and Pfizer Inc with partner BioNTech SE, and inactivated cold virus platforms used by Oxford University/AstraZeneca Plc, Johnson & Johnson and CanSino Biologics, whose vaccine has been approved for military use in China.
Merck & Co in September started testing a COVID-19 vaccine based on a weakened measles virus that delivers genes from the new coronavirus into the body to stimulate an immune response to the coronavirus.
Of these, only the technology offered by J&J and CanSino that use cold viruses as vectors to deliver coronavirus genetic material have ever produced a licensed vaccine - for Ebola.
The next set of candidates - with late-stage trial results expected in the first half of 2021 - are heavily skewed toward approaches that have produced successful vaccines.
Conventional methods include using a killed or inactivated version of the pathogen that causes a disease to provoke an immune response, such as those used to make flu, polio and rabies vaccines.
Also more common are protein-based vaccines that use purified pieces of the virus to spur an immune response. Vaccines against whooping cough, or pertussis, and shingles employ this approach.
French drugmaker Sanofi is developing a protein-based COVID-19 vaccine employing the same approach it uses for its Flublok seasonal flu vaccine. Sanofi expects to start the final phase of testing in early December, with approval targeted in the first half of 2021.
While Novavax Inc has not yet produced a licensed vaccine, it is using similar purified protein technology and expects to start a late-stage U.S. trial involving 30,000 volunteers in late November.
"Those are more traditional approaches, so we can feel more comfortable that we have a lot of experience with them," said Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia.
Offit also sees promise in some of the inactivated virus vaccines being developed by Chinese researchers, including Sinopharm's China National Biotec Group (CNBG), one of the few first-crop developers using a traditional technique.
Other second-wave developers are making vaccines based on virus-like particles (VLPs), which mimic the structure of the coronavirus but contain no genetic material from it.
VLP vaccines can be produced in a variety of different types of cells, including mammal, bacterial, insect, yeast and plant cells. This approach has been used to develop vaccines for hepatitis B and human papillomavirus.
Quebec's Medicago is testing a VLP COVID-19 vaccine grown in tobacco plants with the backing of tobacco company Philip Morris.
Medicago has yet to produce an approved vaccine, but has completed large-scale testing for a seasonal flu vaccine using this approach. It plans to begin mid-stage trials of its COVID-19 vaccine next month and aims to make up to 1 billion doses a year by 2023.
Others are looking at alternative delivery methods, such as the nasal spray vaccine being developed by a team at Xiamen University, Hong Kong University and Beijing Wantai Biological Pharmacy Enterprise, which is based on a modified flu virus.
CHALLENGES AHEAD
The second crop, however, could face problems completing large studies if the current leaders bring their vaccines over the finish line in the coming months.
"If we get a super vaccine in December, from company x, which is on the market, it will be difficult to recruit participants into other studies," said Peter Kremsner from the University Hospital in Tuebingen, Germany.
"Then everyone will say, if the vaccine exists, I will get vaccinated now with this vaccine. This will definitely prove a problem for recruitment,” added Kremsner, who is testing CureVac's mRNA COVID-19 vaccine in early clinical trials with backing from the Bill & Melinda Gates Foundation.
On the flip side, it is easier and faster to prove efficacy when community spread of the virus is rampant as is happening again in the United States, Europe and elsewhere, a potential advantage for companies starting large-scale vaccine trials in the near future.
Reuters
Thu Oct 29 2020
The world will need several different vaccines to fight the COVID-19 pandemic, given the sheer size of global need, variations in effects on different populations, and possible limits of effectiveness in the first crop. REUTERS file pic
Kerja ganti paip lama di Seluruh Sarawak bermula tahun ini
Sarawak akan memulakan kerja-kerja penggantian saluran paip lama sepanjang 2,740 kilometer di seluruh negeri itu bermula tahun ini.
Julaihi beri jaminan bekalan air di Sarawak pada Hari Raya mencukupi
Menteri Utiliti dan Telekomunikasi Sarawak mengingatkan orang ramai supaya elakkan pembaziran meskipun bekalan air ketika Hari Raya nanti dijamin mencukupi.
90 peratus kawasan terlibat kebakaran hutan berjaya dipadamkan
Operasi pemadaman kebakaran hutan di Kuala Baram sejak seminggu lalu berjaya dengan 90 peratus api dikawasan terjejas berjaya dipadamkan.
Pembantu bengkel diberkas, bakar mercun tengah jalan
Tindakan seorang lelaki membakar mercun di tengah jalan ketika menyertai perarakan mengiringi upacara pengebumian dekat pekan Banting di sini mengundang padah apabila diberkas polis pada Rabu.
El Nino: Al-Sultan Abdullah tinjau Sungai Pahang, titah adakan solat hajat
Sultan Pahang Al-Sultan Abdullah Riayatuddin Al-Mustafa Billah Shah berkenan meninjau Sungai Pahang yang dilaporkan surut akibat fenomena El Nino.
Hujan roket Hizbullah gegar utara Israel
Pejuang Hizbullah pada Rabu melancarkan kira-kira 30 roket dari Lubnan ke kawasan utara Israel selepas gerakan disokong Iran itu berikrar untuk 'menghukum' rejim Zionis.
Tol percuma sempena Aidilfitri 8, 9 April - Alexander
Pengguna lebuh raya membabitkan kenderaan persendirian (Kelas 1) diberi kemudahan tol percuma selama dua hari iaitu 8 dan 9 April bersempena dengan sambutan Aidilfitri tahun ini.
Penstriman haram: Jangkitan malware berisiko akibatkan kecurian, penipuan identiti pengguna
Awas dan jangan mudah terpedaya dengan sebarang akses haram yang menawarkan pelbagai filem dan siri televisyen kerana ia mungkin menyimpan perisian hasad atau malware.
Insentif cukai baharu untuk syarikat berstatus Malaysia Digital
Perbadanan Ekonomi Digital Malaysia (MDEC) akan memperkenalkan insentif cukai baharu kepada syarikat berstatus Malaysia Digital (MD) dan syarikat berstatus Koridor Raya Multimedia (MSC) sedia ada.
Gentari setuju saranan tubuh konsortium bantu pemain solar - DPMM
Gentari Sdn Bhd menyatakan persetujuannya dengan saranan untuk mewujudkan konsortium dianggotai pemain industri solar.
China jadikan pengalaman pencegahan COVID-19 untuk hadapi pandemik masa depan
China akan menjadikan pengalaman dalam pencegahan dan kawalan COVID-19 untuk membuat persediaan yang lebih proaktif untuk menghadapi pandemik masa depan seperti "Penyakit X".
Negara berdepan ketirisan subsidi diesel serius - Amir Hamzah
Negara kini sedang berdepan isu ketirisan subsidi diesel yang serius dan wujud kemungkinan terdapat pihak yang tidak layak masih menikmati subsidi itu, kata Menteri Kewangan II Datuk Seri Amir Hamzah.
Kematian akibat kemalangan jalan raya lebih tinggi daripada COVID-19 - Anthony Loke
PDRM akan mengeluarkan data mengenai kemalangan jalan raya pada setiap hari, bukan setahun sekali seperti diamalkan sebelum ini.
Ismail Sabri ziarah lapan beradik yatim piatu akibat COVID-19
Ismail Sabri tiba kira-kira jam 2 petang di kediaman lapan beradik itu di Taman Adenium, Bukit Beruntung pada Selasa.
Teori konspirasi 'Penyakit X'
Ahli teori konspirasi AS sekali lagi membuat 'keuntungan' selepas PBB memberi amaran tentang wabak lebih berbahaya iaitu 'Penyakit X'.
Reformasi dasar, kukuhkan perlindungan, produktiviti pekerja tidak formal
Reformasi dasar perlu dilakukan dalam usaha meningkatkan perlindungan dan produktiviti pekerja tidak formal di Malaysia.
Lebuh raya perlu ada sistem pemberitahuan Smart Lane lebih berkesan - Ahmad Maslan
Semua lebuh raya perlu mewujudkan satu sistem pemberitahuan Smart Lane yang lebih berkesan, bagi mengurangkan kesesakan lalu lintas khususnya ketika cuti perayaan.
Jepun akan mansuh bantuan awam untuk rawatan COVID-19
Kerajaan Jepun memutuskan untuk menamatkan subsidi untuk ubat-ubatan COVID-19 dan kemasukan ke hospital bulan depan, menurut media tempatan.
KUSKOP mudahkan urusan pinjaman usahawan, bantu hadapi kenaikan harga barang
KUSKOP melalui pebagai agensinya, mengambil pendekatan memudah cara urusan pinjaman perniagaan kepada usahawan mikro yang terkesan dengan kenaikan kos dan harga barang.
Ismail Sabri pilih 'tindakan Malaysia dalam perangi COVID-19' sebagai tajuk tesis PhD
Ketika COVID-19 diisytihar sebagai pandemik global pada Mac 2020, Datuk Seri Ismail Sabri Yaakob merupakan Menteri Kanan Pertahanan yang bertanggungjawab terhadap kluster keselamatan.